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Abstract
I In nt tr ro od du uc ct ti io on n: : Bisphosphonates (BPs) can be locally used to improve the
osteogenesis around hydroxyapatite (HA) implants. However, there are almost
no reports discussing the effects of BPs in the bound state with HA on
osteoclasts. Ibandronate is a BP widely used in clinical practice. This study was
designed to evaluate the effects of ibandronate combined with HA on the
morphology and resorptive activity of osteoclasts. 
M Ma at te er ri ia al l   a an nd d   m me et th ho od ds s: :   The HA and ibandronate-HA were prepared. Osteoclasts
were isolated from Sprague-Dawley rats and then the cells were cultured with
both HA and ibandronate-HA. Then the cell morphology was inspected by
inverted phase contrast microscope and transmission electron microscopy
observation.  The  resorptive  activity  was  tested  using  the  dyeing  agent
seminaphthofluorescein and bone resorption assay.
R Re es su ul lt ts s: :   Compared with the control group, the osteoclasts demonstrated
morphological alterations, and the hydrogen ion concentration was significantly
lower in the ibandronate-HA group. Areas of the resorption pits formed by the
osteoclasts were significantly smaller, the trabecula thickness appeared thicker,
and concentration of CTx was also significantly lower in the experimental group. 
C Co on nc cl lu us si io on ns s: :   Resorptive activity of osteoclasts cultured with ibandronate-HA
was weaker than that of the control group. Ibandronate on HA in the bound
state could maintain its action as an inhibitor to osteoclasts.
K Ke ey y   w wo or rd ds s: :   hydroxyapatite, bisphosphonate, osteoclast, biomaterial.
Introduction
Hydroxyapatite (HA) is one of the most commonly used biomaterials
for bone scaffolds or implants in surgery and dentistry because of its
favourable  biocompatibility,  bioactivity  and  osteoconductivity  [1].
Bisphosphonates (BPs) are a variety of compounds that prevent the loss
of bone mass, clinically used for the treatment of osteoporosis and other
disorders of bone metabolism [2]. The BPs, having an affinity for the
calcium ions of HA [3], are proven to be a potent inhibitor of bone
resorption and an effective accelerator of bone regeneration. The unbound
BPs display a common backbone structure of P-C-P . When combined with
HA, the line structure of unbound BPs transfers to a six-membered ring
structure bound state. It is well known that unbound BPs could be ingested
by osteoclasts, activate various effects at the cellular level [4, 5], and then
lead to a decrease in the breakdown of bone in vivo. However, there are
almost no reports discussing the effects of BPs combined with HA, in the
C Co or rr re es sp po on nd di in ng g   a au ut th ho or r: :   
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bound state, on morphology and resorptive activity
of osteoclasts. So it is interesting to study whether
BPs on HA (in the bound state, a six-membered ring
structure) would continue to act as an inhibitor to
osteoclasts. And it could provide experimental
evidence  for  BPs  modifying  HA  to  improve
osteogenesis around HA in vivo. 
Our team has studied the surface properties of
HA modified by BPs and its effects on osteoblasts
[6-8]. To investigate the effects of BPs combined
with HA on resorptive activity of osteoclasts, we
combined  HA  with  ibandronate,  one  of  the
nitrogen-containing BPs used widely in clinical
practice with a high affinity for HA (calcium ions).
Then the morphology and resorptive activity of
osteoclasts of Sprague Dawley rats (SD rats) were
observed by culturing them with ibandronate-HA
and HA for comparison.
Materials and methods
M Ma at te er ri ia al l   p pr re ep pa ar ra at ti io on n
The HA bioceramics for bone scaffolds (40.0 MPa
compressive strength, 15.5 mm diameter round
shape, 0.5 mm thickness) were prepared by the
Research Center for Nano-Biomaterials, Sichuan
University. The ibandronate-HA combination was
carried out according to the method of Luo et al.
[6-8]. Briefly, the scaffolds were immersed into
a solution of 1 mg/ml ibandronate sodium (Sigma-
Aldrich, USA) for 48 h at 37°C with a pH of 6.5 to
form ibandronate-HA chelate. Then the specimens
were cleaned ultrasonically with distilled water for
30 min and then stored in constant temperature
desiccators (as cleaned specimens). The scaffolds
without  ibandronate  were  also  cleaned  and
prepared as a control.
I In n   v vi it tr ro o   r re el le ea as se e   t te es st ti in ng g
Five randomly-selected ibandronate-HA compo  -
sites were rinsed in 1 ml of eluting agent (adjusted
to pH 7.0). After 24 h, the solutions were collected,
and the concentrations of ibandronate were tested
by reverse phase liquid chromatography at 220 nm
[9], using a Waters 1525 binary HPLC pump (Waters
Co., USA), a Rheodyne (Cotati, CA, USA) model 7725i
injection valve fitted with a 20 µl loop, and a Waters
2487 dual ʻ absorbance detector (Waters Co., USA).
Ibandronate in the samples was separated on
a Phenomenex C18 column (USA) at 25°C using
a mixture of acetonitrile and n-amylamine, and the
flow rate was 1 ml/min. Such procedures were
repeated once a day for 14 days.
A An ni im ma al ls s   a an nd d   o os st te eo oc cl la as st t   c cu ul lt tu ur re e
Male rats of SD rat strain (1 day old) were
supplied by the Laboratory Animal Center, Sichuan
University. The animal use and care protocol was
approved by the Institutional Animal Use and Care
Committee of Sichuan University.
Disaggregated osteoclasts were isolated and
cultured according to the method of Chambers et
al. [10]. Briefly, long bones of the rats were dissected
free from soft tissues and sterilized in 75% ethanol
for 5 min. The epiphyses were removed from the
bone, which was split longitudinally with a blade.
Endosteal surfaces were carefully curetted with
a scalpel blade and the bone marrow fragments
were collected into culture medium consisting 
of  Dulbecco's  minimum  essential  medium 
(DMEM) (GIBCO, USA) containing 0.2 g/l glutamine, 
100 IU/ml penicillin, 100 µg/ml streptomycin and
10% heat-inactivated fetal bovine serum (FBS,
Gibco,  USA).  The  bone  marrow  fragments 
were pipetted gently to separate cells from the 
bone fragments. The disaggregated cells were
concentrated by centrifugation at 1000 rpm for 
10  min  and  suspended  into  culture  medium, 
and then maintained at 37°C in an atmosphere of
5% CO2 for 30 min. The non-adherent cells were
washed away with DMEM, and consequently the
adherent cells were collected and cultured at 37°C
in an atmosphere of 5% CO2. Culture medium was
changed every day. The cells were dried and fixed
with methanol for 5 min and stained with 5%
Giemsa solution (Merck, Germany) for 30 min. For
tartrate-resistant acid phosphatase (TRAP) assay,
an Acid Phosphatase, Leukocyte (TRAP) kit (Sigma,
USA) was used according to the manufacturer’s
instructions. Then the cells were observed under
an inverted phase contrast microscope. The TRAP-
positive staining multinuclear (≥ 3 nuclei) cells were
counted as osteoclasts.
O Ob bs se er rv va at ti io on n    o of f    o os st te eo oc cl la as st ts s    c cu ul lt tu ur re ed d    w wi it th h
s sc ca af ff fo ol ld ds s
The ibandronate-HA and untreated HA scaffolds
were placed in wells of 24-well plates and pre-
incubated overnight in cell culture medium. Then
1 ml of cell suspension (4 × 103 cells/ml) was
dripped into each well, so the osteoclasts could
precipitate on the surfaces of the scaffolds. The
scaffolds and cells were cultured at 37°C in an
incubator with a 5% CO2 atmosphere and the
medium was changed every other day.
The cells cultured with the ibandronate-HA or
pure HA scaffolds were viewed under an IX70-S8F2
inverted  phase  contrast  microscope  (IPCM)
(Olympus, Japan) and photographed. For trans  -
mission electron microscopy (TEM) obser  vation,
cells were washed with phosphate buffered solution
(PBS) twice and centrifuged at 4000 rpm for 10 min,
then fixed with 0.3% glutaraldehyde for 12 h. Then,
the cells were centrifuged at 10 000 rpm for 15 min,
and fixed with 3% glutaraldehyde for 2 h. After that,Arch Med Sci 1, February / 2011 55
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the cells were dehydrated in a graded series of
ethanol baths, imbedded in araldite, and then
underwent ultrathin section prior to being observed
under a transmission electron microscope (TEM,
JEM-100CX, JEOL, Japan) at 50 kV.
D De et te er rm mi in na at ti io on n   o of f   h hy yd dr ro og ge en n   i io on n   c co on nc ce en nt tr ra at ti io on n
i in n   o os st te eo oc cl la as st ts s
Osteoclasts of both groups were digested in
0.25% trypsin with 0.02% EDTA from the scaffolds
and blown into cell suspension. The osteoclasts
were treated with 20 mM ammonium chloride for
15 min and washed twice with DMEM free of
phenol red or serum, and then placed into a 12-well
plate  with  blood  cover  slips.  After  that,  the 
cells  were  stained  with  the  dyeing  agent
seminaphthofluorescein (SNAFL), a sort of fluo  -
rescent probe that binds specifically with hydrogen
ions, and incubated at 37°C for 30 min. Twelve
osteoclasts out of each well were selected randomly
to determine the fluorescence intensity under
a confocal microscope with the help of the image
analyzing  software  Laserpix  (Bio-Rad,  USA).
Differences of the data out of each well were ana  -
lysed using t-test with SPSS10.0 (SPSS, Chicago, IL,
USA). Statistical significance was defined as p < 0.05.
B Bo on ne e   s sl li ic ce e   r re es so or rp pt ti io on n   a as ss sa ay y
Freshly dissected bovine tibiae and femora free
from soft tissues were cleaned and sliced into slices
of 5 mm diameter with the thickness of 10-50 µm.
Then the slices were cleaned in double distilled
water ultrasonically and sterilized with epoxye  -
thane, maintained at 4°C in reserve. The bone slices
were resterilized under ultraviolet radiation for 
30 min every time before use.
Osteoclasts of both groups were digested in 0.25%
trypsin  with  0.02%  ethylenediaminetetraacetic 
acid (EDTA, Sigma, Germany) from the scaffolds and
blown into the cell suspension, where density was
adjusted to 2 × 103 cells/ml after cell counting, for
pre-emergency, and seeded into 24-well plates
separately, with equal doses of Dulbecco's modified
Eagle's medium (DMEM) and one piece of bone
slice in each well. The osteoclasts adhere to the
surfaces of slices in 30 min. The cells together with
the  slices  were  incubated  at  37°C,  5%  CO2
atmosphere in a humid incubator. The culture
medium was changed every other day. On the 7th
day, the bone slices seeded with cells were rinsed
with PBS and fixed with 3% glutaric dialdehyde for
60 min, rinsed again with PBS and then fixed with
osmic acid. Afterwards, the slices were dehydrated
in descending series of ethanol (50-100%), soaped
with isoamyl acetate for 30 min. Critical point drying
and sputter coating were performed before the
slices went under the scanning electron microscope
(SEM, JSM-5900LV, JEOL, Japan). A CCD camera was
applied to take the picture of the resorption pits
and Laserpix software (Bio-Rad, USA) was used to
measure the areas of the pits. The 12 largest
resorption pits of each bone slice in every well were
selected to determine the areas. Mean values of
the areas were analysed using t-test with SPSS10.0
(SPSS, Chicago, IL, USA). Statistical significance was
defined as p < 0.05.
The bone microarchitecture at the resorption pits
was analysed with a MicroCT µ-CT80 (SCANCO,
Switzerland) and then three-dimensional micro  -
structural image data were reconstructed and the
trabecular thickness (Tb.Th) of the resorption pits
was measured [11]. The data were then analysed
using t-test with SPSS10.0 (SPSS, Chicago, IL, USA).
Statistical significance was defined as p < 0.05.
Type I collagen is the main component of bones
in mammals. C-telopeptide of type I collagen (CTx)
is a specific breakdown product of type I collagen
during the process of bone resorption, and usually
used as a marker of bone turnover [12]. Levels of
CTx  in  the  medium  were  measured  using  an
enzyme-linked immunosorbent assay (ELISA) kit
(Osteometer  BioTech,  DM)  according  to  the
manufacturer’s instructions. The concentrations of
CTx in each well were measured 3 times and the
average values were then analysed using t-test with
SPSS10.0  (SPSS,  Chicago,  IL,  USA).  Statistical
significance was defined as p < 0.05. 
Results 
I In n   v vi it tr ro o   r re el le ea as se e
During the first 3 days, a sharp decline was
observed in the release testing, indicating a rapid
ibandronate release from the HA scaffold in the
initial period. Then, the release curve went flat from
the  4th day  on,  showing  a slow  release  of
ibandronate. The amount of ibandronate was still
detectable after 14 days (Figure 1).
8000
7000
6000
5000
4000
3000
2000
1000
0
02468 10 12 14
D Da ay ys s
F Fi ig gu ur re e   1 1. .   In vitro release of ibandronate release from
the HA scaffold
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O Os st te eo oc cl la as st t   c cu ul lt tu ur re e   
In  the  early  stage  contained  in  the  cell
suspension are osteoclasts and a great amount of
other cells, mainly erythrocytes, marrow stroma
cells, fibroblasts, etc. The osteoclasts began to
adhere in 30 min, while the non-adherent cells were
rinsed away. Giant multinucleated osteoclasts with
a ruffled border could be clearly distinguished under
the  inverted  phase  contrast  microscope.  The
adherent osteoclasts exhibited polymorphism; they
had round, oval or irregular shapes (Figure 2. A).
In the Giemsa staining specimen, nuclei of the
multinucleated osteoclasts were stained bluish
violet,  containing  1-2  nucleoli  in  each  nucleus 
(Figure 2. B). In the TRAP assay, the TRAP positive
cytoplasm was dyed ruby red while the TRAP
negative nuclei remained unstained (Figure 2. C).
4-20 nuclei could be observed in the multinucleated
osteoclasts.
O Os st te eo oc cl la as st ts s   c cu ul lt tu ur re ed d   w wi it th h   s sc ca af ff fo ol ld ds s
The number of pseudopods decreased markedly
after the osteoclasts were cultured with scaffolds
in  the  ibandronate-HA  group  (Figure  3.  A,  B).
Compared  with  the  control  group,  osteoclasts
cultured with ibandronate-HA were characterized
under TEM by condensation of chromatin, reduced
number of endoplasmic reticuli, lysosomes and
shrinkage  of  Golgi  apparatus.  The  nucleoli
disappeared; the nuclei shrank and became empty
inside (Figure 3. C, D). 
H Hy yd dr ro og ge en n   i io on n   c co on nc ce en nt tr ra at ti io on n   i in n   o os st te eo oc cl la as st ts s
It was observed that relative mean fluorescence
intensity (RMFI) of cells in the ibandronate-HA
group was significantly lower than that in the
control group (p < 0.05) (Figure 4). So it could be
inferred that the hydrogen ion concentration was
lower in the ibandronate-HA group compared with
the control group. 
B Bo on ne e   s sl li ic ce e   r re es so or rp pt ti io on n   a as ss sa ay y
Areas of the resorption pits in the bone slices
formed by the osteoclasts may reflect the resorption
activity. Compared with those of the control group,
areas of the pits formed in the ibandronate-HA group
were significantly smaller (P < 0.05) (Figure 5). 
Applying  MicroCT  and  three-dimensional
reconstruction, we could clearly determine that
Tb.Th at resorption pits in the ibandronate-HA
group was thinner than that in the control group 
(P < 0.05) (Figure 6). 
The concentration of CTx in the ibandronate-HA
group was significantly lower than that in the
control group (P < 0.05) (Figure 7). It could be
inferred that the activity of decomposing type
I collagen  declined  after  the  osteoclasts  were
cultured with ibandronate-HA.
Discussion
In the present study, we investigated the effect
of ibandronate in the bound state on resorptive
activity of osteoclasts in vitro. The results demo  n  -
strated that bound ibandronate is clearly associated
with inhibition of osteoclasts. This study might
provide experimental evidence for studies regarding
the application of BPs modifying HA to improve
osteogenesis around HA in vivo. 
BPs  are  synthetic  analogues  of  inorganic
pyrophosphate, characterized by a P-C-P group. 
The affinity for HA is a property of the P-C-P motif,
because it can chelate calcium ions by bidentate
coordination through the oxygen atoms of the
phosphonate groups [13]. The mechanism of BPs
has not been elucidated yet, but there is general
agreement that the final target of unbound BPs’
action is the osteoclast [14]. 
After being internalized by osteoclasts, BPs start
affecting a series of biochemical processes including
both the recruitment and differentiation of osteoclast
precursors and the adhesion and activity of mature
osteoclasts. Additionally, BPs induce apoptosis of
osteoclasts, leading to a decrease in the breakdown
of bone. Possible mechanisms of action of BPs are
as follows: (a) inhibition of osteoclast recruitment to
the bone surface; (b) inhibition of osteoclast activity
on the bone surface; (c) shortening of the osteoclast
life span; and (d) alteration of bone mineral [15].
A consequence of the first three effects could be
a reduced number of osteoclasts. 
F Fi ig gu ur re e   2 2. .   A A – Multinucleated osteoclast observed under IPCM. B B   – Giemsa staining. C C   – TRAP assay
A B CArch Med Sci 1, February / 2011 57
Effects of ibandronate-hydroxyapatite on resorptive activity of osteoclasts
In this in vitro study, the characteristic morpho  -
logical features of ibandronate-treated osteoclasts
were the lack of ruffled borders, shrunken nuclei
and  decreased  size  of  organelles.  A possible
explanation is that ibandronate was converted
intracellularly to a nonfunctional analogue of ATP
that competed with ATP in the cellular energy
metabolism. The osteoclasts initiated apoptosis and
died [16]. During apoptosis, osteoclasts lost their
cytoskeletal integrity and ruffled borders, nuclei
shrank, and osteoclasts became inactive.
In osteoclastic bone resorption, H+ is produced
from CO2 and H2O by carbonic anhydrase II intra  -
cellularly and secreted extracellularly by H+-ATPase
in  the  membrane  of  the  ruffled  border  [17].
Accumulation of large amounts of protons in the
resorption  lacuna  causes  acidification  of  the
resorption  pit  and  initiates  inorganic  mineral
dissolution. David et al. found that tiludronate,
a non-nitrogenous BP, was a potent inhibitor of
proton-pumping V-ATPase [18]. Clodronate, etidro  -
nate, pamidronate and alendronate could inhibit
vacuolar acidification in some form of metabolic
inhibition,  which  did  not  appear  to  be  direct
inhibition of ATPase [19]. Our results demonstrated
that bound ibandronate could lead to a decline of
intracellular proton concentration. This is consistent
with the previous findings.
Effects of immobilized BPs on bone defect
repair or osteogenesis around HA-coated implants
have been investigated in some in vivo studies.
The  results  demonstrated  that  BPs  could
accelerate  bone  defect  repair  and  improved
osteogenesis around HA [20]. But few mechanisms
have  been  described.  Our  findings  could 
give a possible explanation in terms of bone
remodelling.  After  HA  is  implanted  into  the
defects, the bone tissue will undergo a process of
remodelling according to the basic multicellular
unit theory [21]. It is expected that the osteogenic
activity will gain the advantage in the formation
phase of bone remodelling for the successful
A B
C D
F Fi ig gu ur re e   3 3. .   Osteoclasts of both groups after being cultured with scaffolds through IPCM and TEM. The pseudopods of
osteoclasts in ibandronate-HA groups decreased markedly with shrunk or empty nuclei (as the arrows indicate) (A A),
while nuclei of osteoclasts cultured with HA have a basically normal shape (B B). Osteoclasts cultured with ibandronate-
HA had collapsed nuclei and shrunken organelles (as the arrows indicate) (C C). Osteoclasts in the control group had
basically normal organelles (D D)58 Arch Med Sci 1, February / 2011
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F Fi ig gu ur re e   4 4. .   Osteoclasts in both groups stained by
SNAFL through confocal microscope. Hydrogen ion
concentration in the ibandronate-HA group was
lower, and osteoclasts stained by SNAFL had weaker
fluorescence intensity (A A) compared with the control
group (B B)
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F Fi ig gu ur re e    5 5. .    Osteoclasts  in  ibandronate-HA  group
formed  smaller  resorption  pits  (as  the  arrows
indicate) (A A) compared with the control group (B B)
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restoration  of  the  bone  defect.  However,
osteoclasts remain hyperactive in the formation
phase due to injury, local infection, undesirable
stress and poor biocompatibility of biomaterials,
which  may  lead  to  peri-HA  osteolysis  and
subsequent loosening [22]. Therefore, when the
activity of osteoclasts at the HA implant site is
moderately inhibited by BPs in the bone formation
phase, both the osteogenesis around the implants
and  the  biointegration  between  bones  and
implants are improved. In clinical practice, if HA
scaffolds or HA-coated implants are used in sites
involved  by  infection,  undesirable  stress,  or
osteoporosis [23], pre-treatment with BPs might
be a novel and effective option. Further study is
required to more precisely define the proper types
of BPs, the release dose, and the methods of
combining BPs with HA.
In this study, rat osteoclasts were cultured with
ibandronate-HA and untreated HA scaffolds. Results
showed that, compared with those cultured with
untreated  HA,  ibandronate-HA  could  lead  to
osteoclasts’ morphological changes and weaker
resorptive activity. Evidence was obtained indicating
that ibandronate on HA in the bound state could
continue to act as an inhibitor to osteoclasts, and
further experiments should be done to confirm this
conclusion.
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F Fi ig gu ur re e   6 6. .   Resorption pits in 3-D reconstruction of
microCT. Tb.Th at resorption pit in the ibandronate-
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